Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG for Resistant Neuropathic Pain
NCT00850005Phase 2Unknown
- Sponsor
- University of Calgary
- Start
- Feb 2009
- Primary completion
- Jul 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of intravenous human immunoglobulin in neuropathic pain, sponsored by University of Calgary. Primary endpoint: Mean daily pain diary score at 4 weeks. Status: unknown.
02
Drugs
intravenous human immunoglobulin
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT00850005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00850005.